《大行報告》瑞信升康哲藥業(00867.HK)評級至「跑贏大市」 目標價上調至14.5元
瑞信發表研究報告,升康哲藥業(00867.HK)評級,由「中性」上調至「跑贏大市」,目標價由14元上調至14.5元。該行上調對該股今年至2025年各年每股盈利預測3.8%至6.7%,主要基於微降收入預測,輕微上調毛利率預測及下調銷售成本估算。該行認為公司有強勁的零售業務,可更好地抵禦反貪影響,且有更高的派息比率。
該行又指,公司上半年收入按年升3.6%,大致符合市場及該行預期。純利按年升6.8%則勝市場及該行預期,主要受益於勝預期的毛利率,低於預期的銷售開支比率及高於預期的其他收入。當中毛利率按年升0.9個百分點至78.2%。期內藥物銷售按年升7.1%,當中眼科及皮膚科藥物銷售分別按年升29.6%及27.4%,心血管及消化系統藥物銷售按年僅升5.9%及4.2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.